SCHEDULE 13G/A: Bleichroeder LP Discloses 9.99% Stake in Evoke Pharma, Inc. Through Common Shares and Warrants

Bleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, has filed an amended Schedule 13G disclosing a 9.99% beneficial ownership stake in Evoke Pharma, Inc., comprising common shares and warrants, subject to a beneficial ownership limitation.

Summary

• Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach collectively reported beneficial ownership of 158,058 shares of Evoke Pharma, Inc. common stock.
• This aggregate amount represents 9.99% of the outstanding common shares of Evoke Pharma, Inc.
• The ownership includes 68,750 shares of common stock and 89,308 shares issuable upon the exercise of warrants.
• The exercise of warrants is subject to a Beneficial Ownership Limitation of 9.99% of the number of shares outstanding immediately after giving effect to the issuance.
• Without this 9.99% limitation, Bleichroeder would be deemed to beneficially own 408,495 shares (68,750 common shares + 339,745 warrant shares), representing 22.29% of the outstanding shares.
• The Denise and Michael Kellen Foundation, for which Bleichroeder acts as investment adviser, holds the 68,750 common shares (4.61%) and the 89,308 exercisable warrants.
• The Foundation also holds additional warrants that, if fully exercisable without the limitation, would bring its total beneficial ownership to 408,495 shares, or 22.29%.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates a significant, non-activist investment by a reputable firm, suggesting confidence in the company. The beneficial ownership limitation on warrants is a minor constraint but does not detract significantly from the overall positive signal of the investment.

Positives

• A significant institutional investor, Bleichroeder LP, has disclosed a substantial beneficial ownership stake in Evoke Pharma, Inc., which can be viewed as a vote of confidence.
• The filing indicates a long-term investment strategy, as the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Risks

• The beneficial ownership limitation of 9.99% on warrant exercise restricts the immediate full conversion of all held warrants, potentially limiting the reporting persons' direct influence or full economic exposure to the company's upside.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Evoke Pharma, Inc.'s future performance or strategic direction.

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment firm in a publicly traded pharmaceutical company. It does not provide specific insights into broader industry trends or competitive landscape beyond the ownership stake itself.

Related Party Transactions

• Bleichroeder LP acts as the investment adviser for The Denise and Michael Kellen Foundation, which holds a significant portion of the common shares and warrants in Evoke Pharma, Inc. This relationship indicates a coordinated investment strategy between the reporting persons and the foundation.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may be viewed positively, potentially increasing investor confidence and market interest in Evoke Pharma, Inc.

Key Dates

Keywords

Evoke Pharma, Bleichroeder LP, Schedule 13G, Beneficial Ownership, Common Shares, Warrants, Investment Adviser, SEC Filing, Institutional Investor, Ownership Disclosure